PriceTargets.com logo

Neurocrine Biosciences - NBIX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $166.00
  • Forecasted Upside: 22.58%
  • Number of Analysts: 23
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 17 Buy Ratings
  • 1 Strong Buy Ratings
$135.42 As of 12/20/2024 06:31 PM ET
▲ +0.46 (0.34%)

This chart shows the closing price for NBIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neurocrine Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBIX

Analyst Price Target is $166.00
▲ +22.58% Upside Potential
This price target is based on 23 analysts offering 12 month price targets for Neurocrine Biosciences in the last 3 months. The average price target is $166.00, with a high forecast of $219.00 and a low forecast of $114.00. The average price target represents a 22.58% upside from the last price of $135.42.

This chart shows the closing price for NBIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 23 investment analysts is to moderate buy stock in Neurocrine Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 18 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 18 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 18 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 17 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2024Needham & Company LLCReiterated RatingHold ➝ Hold
12/16/2024William BlairReiterated RatingOutperform
12/16/2024WedbushReiterated RatingOutperform ➝ Outperform$148.00 ➝ $148.00
12/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$190.00 ➝ $190.00
11/11/2024Needham & Company LLCReiterated RatingHold
11/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$190.00 ➝ $190.00
10/29/2024Needham & Company LLCReiterated RatingHold
10/17/2024BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$128.00 ➝ $114.00
10/10/2024Raymond JamesReiterated RatingOutperform$155.00
10/4/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$136.00 ➝ $133.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$155.00 ➝ $155.00
9/9/2024BarclaysLower TargetOverweight ➝ Overweight$180.00 ➝ $160.00
8/29/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$170.00 ➝ $155.00
8/29/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$143.00 ➝ $136.00
8/29/2024BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$142.00 ➝ $128.00
8/29/2024Needham & Company LLCReiterated RatingHold
8/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$190.00 ➝ $190.00
8/29/2024Piper SandlerUpgradeNeutral ➝ Overweight$131.00 ➝ $159.00
8/19/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$177.00 ➝ $189.00
8/7/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$173.00 ➝ $181.00
8/5/2024HC WainwrightBoost TargetBuy ➝ Buy$160.00 ➝ $190.00
8/2/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$136.00 ➝ $143.00
8/2/2024GuggenheimBoost TargetBuy ➝ Buy$170.00 ➝ $180.00
8/2/2024OppenheimerBoost TargetOutperform ➝ Outperform$216.00 ➝ $219.00
8/2/2024CitigroupBoost TargetNeutral ➝ Neutral$150.00 ➝ $158.00
8/2/2024BarclaysBoost TargetOverweight ➝ Overweight$169.00 ➝ $180.00
8/2/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$157.00 ➝ $180.00
8/1/2024Needham & Company LLCReiterated RatingHold
7/25/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$155.00 ➝ $155.00
7/25/2024Needham & Company LLCReiterated RatingHold
7/12/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$160.00 ➝ $170.00
7/10/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$169.00 ➝ $173.00
6/12/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
5/29/2024WedbushReiterated RatingOutperform ➝ Outperform$152.00 ➝ $152.00
5/28/2024UBS GroupBoost TargetBuy ➝ Buy$174.00 ➝ $193.00
5/14/2024Evercore ISIInitiated CoverageOutperform$175.00
5/13/2024Evercore ISIUpgradeStrong-Buy
5/3/2024CitigroupBoost TargetNeutral ➝ Neutral$140.00 ➝ $150.00
5/2/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$154.00 ➝ $164.00
5/2/2024GuggenheimBoost TargetBuy ➝ Buy$164.00 ➝ $170.00
5/2/2024BarclaysBoost TargetOverweight ➝ Overweight$150.00 ➝ $169.00
5/2/2024BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$129.00 ➝ $138.00
5/2/2024OppenheimerBoost TargetOutperform ➝ Outperform$200.00 ➝ $216.00
5/2/2024HC WainwrightBoost TargetBuy ➝ Buy$150.00 ➝ $160.00
5/1/2024Needham & Company LLCReiterated RatingHold
4/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$150.00
4/24/2024OppenheimerReiterated RatingOutperform ➝ Outperform$200.00 ➝ $200.00
4/24/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$140.00 ➝ $170.00
4/23/2024Needham & Company LLCReiterated RatingHold
4/17/2024WedbushReiterated RatingOutperform ➝ Outperform$147.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$155.00
3/20/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$148.00 ➝ $158.00
2/23/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$154.00 ➝ $148.00
2/8/2024CitigroupLower TargetNeutral ➝ Neutral$141.00 ➝ $140.00
2/8/2024MizuhoBoost TargetNeutral ➝ Neutral$116.00 ➝ $140.00
2/8/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$127.00 ➝ $140.00
1/25/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$134.00 ➝ $153.00
1/23/2024BarclaysBoost TargetOverweight ➝ Overweight$145.00 ➝ $150.00
12/18/2023Stifel NicolausBoost TargetBuy ➝ Buy$141.00 ➝ $144.00
12/13/2023Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$110.00 ➝ $127.00
12/13/2023CitigroupInitiated CoverageNeutral$127.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$136.00
12/7/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$150.00
11/10/2023MizuhoLower TargetNeutral ➝ Neutral$116.00 ➝ $114.00
11/10/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$128.00 ➝ $121.00
11/10/2023BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$111.00 ➝ $100.00
11/3/2023MizuhoBoost TargetNeutral ➝ Neutral$113.00 ➝ $116.00
11/1/2023Piper SandlerBoost TargetNeutral ➝ Neutral$95.00 ➝ $100.00
11/1/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$123.00 ➝ $128.00
11/1/2023Raymond JamesBoost TargetOutperform ➝ Outperform$135.00 ➝ $145.00
10/24/2023Cantor FitzgeraldReiterated RatingOverweight
10/8/2023Bank of AmericaBoost Target$137.00 ➝ $143.00
10/6/2023Leerink PartnersBoost Target$125.00 ➝ $135.00
10/6/2023Robert W. BairdBoost Target$152.00 ➝ $157.00
10/6/2023OppenheimerBoost TargetOutperform ➝ Outperform$160.00 ➝ $165.00
10/6/2023HC WainwrightBoost TargetBuy ➝ Buy$146.00 ➝ $150.00
9/21/2023BarclaysBoost Target$125.00 ➝ $134.00
9/13/2023MizuhoReiterated RatingNeutral ➝ Neutral$113.00
9/13/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$132.00 ➝ $144.00
9/13/2023Robert W. BairdBoost Target$148.00 ➝ $152.00
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$146.00
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$136.00
9/13/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$133.00 ➝ $134.00
9/13/2023WedbushBoost TargetOutperform ➝ Outperform$120.00 ➝ $137.00
9/13/2023BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$100.00 ➝ $111.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$136.00
8/21/2023MizuhoBoost TargetNeutral$112.00 ➝ $113.00
8/21/2023Jefferies Financial GroupBoost Target$123.00
8/21/2023OppenheimerBoost TargetOutperform ➝ Outperform$150.00 ➝ $154.00
8/21/2023HC WainwrightBoost TargetBuy ➝ Buy$140.00 ➝ $146.00
8/2/2023OppenheimerReiterated RatingOutperform ➝ Outperform$150.00
8/2/2023BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$96.00 ➝ $100.00
8/2/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$130.00
8/2/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$108.00 ➝ $110.00
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$140.00
8/2/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$130.00 ➝ $132.00
8/2/2023Cantor FitzgeraldBoost Target$127.00 ➝ $135.00
8/2/2023MizuhoBoost TargetNeutral ➝ Neutral$111.00 ➝ $112.00
8/2/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$140.00 ➝ $148.00
7/24/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform
7/24/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$115.00 ➝ $125.00
7/6/2023BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$91.00 ➝ $96.00
6/30/2023Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$108.00
6/6/2023Stifel NicolausLower Target$145.00 ➝ $125.00
6/5/2023Royal Bank of CanadaBoost Target$106.00 ➝ $108.00
5/4/2023MizuhoLower Target$116.00 ➝ $111.00
5/4/2023CitigroupLower Target$127.00 ➝ $122.00
5/4/2023BarclaysLower Target$131.00 ➝ $125.00
5/4/2023GuggenheimUpgradeNeutral ➝ Buy$145.00
4/24/2023Royal Bank of CanadaBoost Target$108.00 ➝ $110.00
4/19/2023CitigroupLower TargetBuy$131.00 ➝ $127.00
4/17/2023WedbushLower TargetOutperform$131.00 ➝ $128.00
4/14/2023MizuhoReiterated RatingNeutral$116.00
4/4/2023UBS GroupLower TargetBuy$137.00 ➝ $125.00
3/30/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$124.00 ➝ $132.00
3/3/2023Evercore ISIUpgradeIn-Line ➝ Outperform$130.00
2/7/2023Royal Bank of CanadaLower TargetSector Perform$122.00 ➝ $110.00
2/7/2023Wells Fargo & CompanyLower TargetEqual Weight$120.00 ➝ $115.00
2/7/2023HC WainwrightReiterated RatingBuy$140.00
2/7/2023MizuhoReiterated RatingNeutral$116.00
2/7/2023Cantor FitzgeraldLower TargetOverweight$132.00 ➝ $127.00
2/7/2023WedbushBoost TargetOutperform$125.00 ➝ $131.00
2/7/2023CitigroupLower TargetBuy$133.00 ➝ $131.00
2/7/2023BarclaysLower TargetOverweight$136.00 ➝ $131.00
2/7/2023Piper SandlerLower TargetNeutral$103.00 ➝ $95.00
2/3/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$120.00 ➝ $130.00
11/3/2022Raymond JamesBoost TargetOutperform$125.00 ➝ $135.00
11/3/2022JPMorgan Chase & Co.Boost TargetOverweight$138.00 ➝ $143.00
11/2/2022MizuhoBoost TargetNeutral$105.00 ➝ $116.00
11/2/2022BMO Capital MarketsBoost Target$78.00 ➝ $101.00
11/2/2022Morgan StanleyBoost TargetEqual Weight$102.00 ➝ $120.00
11/2/2022Wells Fargo & CompanyBoost TargetEqual Weight$110.00 ➝ $120.00
11/2/2022Royal Bank of CanadaBoost TargetSector Perform$101.00 ➝ $117.00
11/2/2022Cantor FitzgeraldBoost TargetOverweight$127.00 ➝ $132.00
11/2/2022Robert W. BairdBoost Target$125.00 ➝ $150.00
11/2/2022Piper SandlerBoost TargetNeutral$91.00 ➝ $103.00
11/2/2022Leerink PartnersBoost TargetMarket Perform$100.00 ➝ $115.00
10/24/2022CitigroupBoost TargetBuy$114.00 ➝ $128.00
10/20/2022MizuhoBoost TargetNeutral$98.00 ➝ $105.00
10/11/2022UBS GroupInitiated CoverageBuy$136.00
9/26/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$110.00
8/8/2022MizuhoBoost TargetNeutral$95.00 ➝ $98.00
8/5/2022Robert W. BairdBoost Target$117.00 ➝ $125.00
8/5/2022BarclaysBoost TargetOverweight$110.00 ➝ $113.00
7/15/2022Morgan StanleyBoost TargetEqual Weight$100.00 ➝ $102.00
4/28/2022WedbushReiterated RatingOutperform
4/12/2022BarclaysBoost TargetOverweight$100.00 ➝ $110.00
4/4/2022JPMorgan Chase & Co.Boost TargetOverweight$125.00 ➝ $126.00
3/3/2022Jefferies Financial GroupDowngradeHold$94.00
3/3/2022Piper SandlerDowngradeOverweight ➝ Neutral$114.00 ➝ $94.00
2/24/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$115.00
2/14/2022HC WainwrightReiterated RatingBuy$140.00
2/14/2022Morgan StanleyBoost TargetEqual Weight$95.00 ➝ $100.00
2/14/2022MizuhoLower Target$103.00 ➝ $95.00
2/11/2022Raymond JamesReiterated RatingBuy$125.00
2/1/2022Morgan StanleyLower TargetEqual Weight$103.00 ➝ $95.00
1/26/2022Piper SandlerLower Target$123.00 ➝ $114.00
1/20/2022BarclaysLower TargetOverweight$110.00 ➝ $100.00
1/18/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$122.00 ➝ $90.00
1/7/2022HC WainwrightReiterated RatingBuy$140.00
1/7/2022Morgan StanleyLower TargetEqual Weight$112.00 ➝ $103.00
12/8/2021HC WainwrightReiterated RatingBuy$139.00
12/8/2021OppenheimerBoost TargetOutperform ➝ Outperform$140.00 ➝ $154.00
12/8/2021CitigroupBoost TargetBuy ➝ Buy$127.00 ➝ $129.00
11/18/2021BMO Capital MarketsInitiated CoverageUnderperform$76.00
11/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$124.00
11/2/2021CitigroupLower TargetBuy$132.00 ➝ $127.00
11/2/2021Raymond JamesLower TargetOutperform$163.00 ➝ $150.00
11/2/2021Royal Bank of CanadaLower TargetOutperform$130.00 ➝ $119.00
11/2/2021MizuhoBoost TargetNeutral$99.00 ➝ $103.00
11/2/2021Cantor FitzgeraldBoost TargetOverweight$117.00 ➝ $123.00
10/18/2021Leerink PartnersReiterated RatingMarket Perform
10/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$110.00 ➝ $112.00
9/30/2021HC WainwrightReiterated RatingBuy
9/22/2021Needham & Company LLCInitiated CoverageHold
8/4/2021Morgan StanleyLower TargetOverweight$116.00 ➝ $110.00
7/16/2021HC WainwrightReiterated RatingBuy$140.00
5/18/2021The Goldman Sachs GroupInitiated CoverageNeutral$108.00
5/6/2021WedbushLower Target$112.00 ➝ $107.00
5/6/2021OppenheimerLower Target$145.00 ➝ $140.00
5/6/2021Morgan StanleyLower TargetOverweight$125.00 ➝ $116.00
5/6/2021Leerink PartnersLower TargetMarket Perform$110.00 ➝ $100.00
5/6/2021BarclaysUpgradeEqual Weight ➝ Overweight$110.00
5/3/2021MizuhoLower TargetNeutral$119.00 ➝ $116.00
4/26/2021MizuhoLower TargetIn-Line ➝ Neutral$119.00 ➝ $116.00
4/19/2021Morgan StanleyBoost TargetOverweight$121.00 ➝ $125.00
4/12/2021WedbushLower TargetOutperform$126.00 ➝ $112.00
3/5/2021Robert W. BairdReiterated RatingBuy
2/5/2021MizuhoBoost TargetNeutral$117.00 ➝ $119.00
2/1/2021Raymond JamesInitiated CoverageOutperform$163.00 ➝ $163.00
1/26/2021William BlairReiterated RatingBuy
12/29/2020Cantor FitzgeraldLower TargetOverweight$168.00 ➝ $121.00
12/16/2020Morgan StanleyLower TargetOverweight$133.00 ➝ $121.00
12/7/2020WedbushLower TargetOutperform$129.00 ➝ $121.00
11/10/2020OppenheimerLower Target$150.00 ➝ $145.00
11/10/2020Smith Barney CitigroupLower Target$149.00 ➝ $138.00
11/10/2020William BlairReiterated RatingOutperform
11/10/2020WedbushLower TargetOutperform$147.00 ➝ $129.00
11/10/2020Credit Suisse GroupLower TargetNeutral$105.00 ➝ $90.00
11/10/2020MizuhoLower TargetNeutral$132.00 ➝ $117.00
11/10/2020Leerink PartnersLower TargetMarket Perform$120.00 ➝ $100.00
10/29/2020OppenheimerLower TargetOutperform$155.00 ➝ $150.00
9/30/2020BenchmarkInitiated CoverageHold
8/4/2020Credit Suisse GroupLower TargetNeutral$135.00 ➝ $126.00
8/4/2020Morgan StanleyLower TargetOverweight$149.00 ➝ $146.00
8/4/2020HC WainwrightBoost TargetBuy$131.00 ➝ $140.00
8/4/2020Cantor FitzgeraldBoost TargetOverweight$144.00 ➝ $161.00
8/4/2020MizuhoBoost TargetNeutral$127.00 ➝ $132.00
8/4/2020Leerink PartnersBoost TargetMarket Perform$105.00 ➝ $120.00
8/4/2020Piper SandlerBoost TargetOverweight$141.00 ➝ $145.00
8/4/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$136.00
7/23/2020MizuhoBoost TargetNeutral$105.00 ➝ $127.00
7/20/2020Credit Suisse GroupBoost TargetNeutral$101.00 ➝ $135.00
7/17/2020OppenheimerBoost TargetOutperform$142.00 ➝ $152.00
7/15/2020Morgan StanleyBoost TargetOverweight$120.00 ➝ $149.00
6/29/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$135.00
6/26/2020CitigroupBoost TargetBuy$124.00 ➝ $149.00
6/18/2020JPMorgan Chase & Co.Boost TargetIn-Line ➝ Overweight$122.00 ➝ $134.00
6/18/2020Royal Bank of CanadaBoost TargetOutperform$116.00 ➝ $135.00
6/17/2020HC WainwrightReiterated RatingBuy$125.00 ➝ $131.00
6/16/2020Needham & Company LLCInitiated CoverageHold
6/16/2020OppenheimerInitiated CoverageBuy$142.00
6/8/2020WedbushInitiated CoverageOutperform$147.00
6/1/2020Piper SandlerReiterated RatingBuy$126.00
5/7/2020BarclaysBoost TargetEqual Weight$105.00 ➝ $108.00
5/7/2020MizuhoBoost TargetNeutral$103.00 ➝ $105.00
5/7/2020Morgan StanleyLower TargetBuy$121.00 ➝ $120.00
5/7/2020HC WainwrightReiterated RatingBuy$125.00
5/7/2020Needham & Company LLCReiterated RatingHold
4/30/2020William BlairReiterated RatingBuy
4/27/2020Needham & Company LLCReiterated RatingHold
4/13/2020OppenheimerLower TargetOutperform$132.00 ➝ $130.00
4/8/2020Piper SandlerLower Target$147.00 ➝ $125.00
4/8/2020Needham & Company LLCReiterated RatingHold ➝ Neutral
4/8/2020Royal Bank of CanadaReiterated RatingBuy$104.00
3/5/2020CitigroupInitiated CoverageBuy$124.00
2/27/2020BarclaysInitiated CoverageEqual Weight$105.00
2/24/2020William BlairInitiated CoverageOutperform$116.00
2/14/2020Stifel NicolausReiterated RatingBuy$127.00
2/5/2020MizuhoInitiated CoverageNeutral$107.00
2/5/2020HC WainwrightReiterated RatingBuy$102.00 ➝ $125.00
1/20/2020Royal Bank of CanadaReiterated RatingBuy$125.00
1/17/2020Morgan StanleyBoost TargetOverweight$120.00 ➝ $121.00
1/13/2020OppenheimerBoost TargetOutperform$115.00 ➝ $132.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.32 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 33 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 24 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 20 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 26 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 28 very positive mentions
  • 24 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 17 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 32 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 69 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 69 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $135.42
Low: $134.12
High: $137.01

50 Day Range

MA: $123.99
Low: $115.08
High: $136.69

52 Week Range

Now: $135.42
Low: $110.95
High: $157.98

Volume

2,265,589 shs

Average Volume

884,102 shs

Market Capitalization

$13.71 billion

P/E Ratio

36.31

Dividend Yield

N/A

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Neurocrine Biosciences?

The following Wall Street sell-side analysts have issued research reports on Neurocrine Biosciences in the last twelve months: Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, StockNews.com, The Goldman Sachs Group, Inc., UBS Group AG, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for NBIX.

What is the current price target for Neurocrine Biosciences?

0 Wall Street analysts have set twelve-month price targets for Neurocrine Biosciences in the last year. Their average twelve-month price target is $166.00, suggesting a possible upside of 22.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting NBIX will reach $219.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $114.00 for Neurocrine Biosciences in the next year.
View the latest price targets for NBIX.

What is the current consensus analyst rating for Neurocrine Biosciences?

Neurocrine Biosciences currently has 5 hold ratings, 17 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NBIX.

What other companies compete with Neurocrine Biosciences?

Other companies that are similar to Neurocrine Biosciences include Alnylam Pharmaceuticals, Biogen, United Therapeutics, Incyte and BioMarin Pharmaceutical. Learn More about companies similar to Neurocrine Biosciences.

How do I contact Neurocrine Biosciences' investor relations team?

Neurocrine Biosciences' physical mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company's listed phone number is (858) 617-7600 and its investor relations email address is [email protected]. The official website for Neurocrine Biosciences is www.neurocrine.com. Learn More about contacing Neurocrine Biosciences investor relations.